Latest on Medically in Neurology
medwireNews from Springer Healthcare: Flortaucipir PET discriminates AD from other neurodegenerative disorders
The positron emission tomography (PET) tracer [18F]flortaucipir could be a useful test for distinguishing Alzheimer’s disease (AD) from other neurodegenerative disorders, say researchers.
medwireNews from Springer Healthcare: Fingolimod shows relapse benefits versus interferon beta-1a in paediatric multiple sclerosis
Adolescents with multiple sclerosis may experience fewer relapses if they take fingolimod versus interferon beta-1a, suggest findings from the phase III PARADIGMS trial.
medwireNews from Springer Healthcare: Biomarkers identified for diagnosing AD in patients with Down syndrome
Plasma neurofilament light protein (NfL) concentrations and cerebrospinal fluid (CSF) biomarkers are effective for diagnosing Alzheimer’s disease (AD) in patients with Down syndrome, say researchers.
medwireNews from Springer Healthcare: Ibudilast slows brain shrinkage in progressive multiple sclerosis patients
Ibudilast may slow brain atrophy in patients with progressive multiple sclerosis, show findings from a phase II study.
medwireNews from Springer Healthcare: Novel MS subtype suggests neurodegeneration and demyelination occur independently
Researchers have discovered a new subtype of multiple sclerosis (MS) that features neuronal loss but not demyelination of the brain’s white matter.
medwireNews from Springer Healthcare: Recognising the risk of increased suicide following TBI
Findings from a large registry-based study support an increased risk of suicide following traumatic brain injury (TBI).
medwireNews from Springer Healthcare: Lower risk of disability progression in primary progressive versus progressive-relapsing MS
Superimposed relapses are associated with a lower risk of confirmed disability progression among individuals with progressive-onset multiple sclerosis (MS), suggest the results of an observational cohort study published in JAMA Neurology
medwireNews from Springer Healthcare: Apomorphine infusion reduces ‘off time’ in patients with Parkinson’s disease
Subcutaneous apomorphine infusion meaningfully reduces the time in which a patient’s medication is not working optimally and parkinsonian symptoms return, reports the placebo-controlled, multicentre TOLEDO trial.
medwireNews from Springer Healthcare: Occipital GABA levels reduced in Parkinson’s patients with visual hallucinations
Reduced levels of γ-aminobutyric acid (GABA) in the primary visual cortex are linked to visual hallucinations in patients with Parkinson’s disease (PD), study findings indicate.
Alzheimer's disease in Medically
This slide provides an overview of the key unmet needs in Alzheimer's disease
Alzheimer's disease: A Global Challenge
This video describes the immense challenge the societies have to face with Alzheimer's disease. This challenge is growing and disease becoming epidemic in the future, and remains the only major disease without any available disease-modifying therapy.
Alzheimer's disease: Mechanism of disease
This video illustrates the latest understanding around the mechanism of disease and the main pathways being targeted to develop new treatment for Alzheimer's disease